v3.26.1
Segment and Geographic Information (Tables)
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Schedule of Net Revenue by Operating Segments and Geographic Region
The following table presents net revenue by operating segment and geographic region (in thousands):
Three Months Ended
June 30,		Six Months Ended
June 30,
2026202520262025
Cardiopulmonary
United States$72,793 $71,243 $142,072 $132,077 
Europe (1)
61,959 49,046 119,263 93,553 
Rest of World (1)
86,824 78,983 168,896 149,962 
221,576 199,272 430,231 375,592 
Neuromodulation
United States126,556 117,226 241,956 225,560 
Europe (1)
19,858 17,730 38,206 32,924 
Rest of World (1)
20,531 16,714 38,571 32,079 
166,945 151,670 318,733 290,563 
Other Revenue (2)
2,066 1,582 3,881 3,224 
Total Company
United States199,350 188,474 384,028 357,638 
Europe (1)
81,817 66,776 157,469 126,477 
Rest of World (1)
109,420 97,274 211,348 185,264 
$390,587 $352,524 $752,845 $669,379 
(1)“Europe” includes the UK, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, and Denmark. Excluding Europe and the U.S., “Rest of World” includes all other countries where LivaNova operates.
(2)“Other Revenue” includes rental and site services income not allocated to segments.
Schedule of Segment Reporting
The following table presents a reconciliation of segment income to consolidated income (loss) before income tax (in thousands):
Three Months Ended
June 30,		Six Months Ended
June 30,
2026202520262025
Cardiopulmonary$28,152 $31,407 $58,219 $56,098 
Neuromodulation60,935 56,020 105,089 108,373 
Segment income89,087 87,427 163,308 164,471 
Other expense(39,603)(33,244)(72,353)(61,671)
Operating income49,484 54,183 90,955 102,800 
SNIA environmental liability expense— (1,677)— (362,070)
Interest expense (1)
(7,176)(14,931)(15,467)(30,217)
Foreign exchange and other income/(expense)(23,829)(4,255)(29,524)7,161 
Income (loss) before income tax$18,479 $33,320 $45,964 $(282,326)
(1)“Interest expense” includes contractual interest expense associated with LivaNova’s short- and long-term financing arrangements and the amortization of debt discount and issuance costs of $4.9 million and $9.7 million for the three and six months ended June 30, 2026, respectively, and $5.7 million and $11.4 million for the three and six months ended June 30, 2025, respectively.
The following table presents the components of segment income, including significant expenses, of LivaNova’s reportable segments (in thousands):
CardiopulmonaryNeuromodulation
Three Months Ended
June 30,		Three Months Ended
June 30,
2026202520262025
Net revenue$221,576 $199,272 $166,945 $151,670 
Less:
Cost of sales97,265 95,465 14,455 14,769 
Selling, general, and administrative66,465 56,012 56,568 51,097 
Research and development18,376 16,465 34,987 29,784 
3T litigation provision11,318 (77)— — 
$28,152 $31,407 $60,935 $56,020 
CardiopulmonaryNeuromodulation
Six Months Ended
June 30,		Six Months Ended
June 30,
2026202520262025
Net revenue$430,231 $375,592 $318,733 $290,563 
Less:
Cost of sales198,194 180,385 28,676 28,155 
Selling, general, and administrative126,314 109,971 109,187 98,667 
Research and development36,171 28,509 75,781 55,368 
3T litigation provision11,333 629 — — 
$58,219 $56,098 $105,089 $108,373 
The following table presents assets by reportable segment (in thousands):
June 30, 2026December 31, 2025
Cardiopulmonary$1,051,493 $1,045,189 
Neuromodulation651,784 639,742 
Other assets (1)
937,584 921,122 
$2,640,861 $2,606,053 
(1)“Other assets” primarily include corporate assets not allocated to segments.
The following table presents capital expenditures by segment (in thousands):
Three Months Ended
June 30,		Six Months Ended
June 30,
2026202520262025
Cardiopulmonary$12,531 $8,767 $22,940 $13,936 
Neuromodulation7,780 4,217 16,623 6,250 
Other capital expenditures (1)
7,286 4,389 11,695 7,491 
$27,597 $17,373 $51,258 $27,677 
(1)“Other capital expenditures” primarily includes corporate capital expenditures not allocated to segments.
Schedule of Changes in Carrying Amount of Goodwill
The following table presents changes in the carrying amount of goodwill by reportable segment for the six months ended June 30, 2026 (in thousands):
CardiopulmonaryNeuromodulationTotal
December 31, 2025$394,086 $398,754 $792,840 
Foreign currency adjustments(13,696)— (13,696)
June 30, 2026$380,390 $398,754 $779,144 
Schedule of Property, Plant, and Equipment, Net by Geographic Region
The following table presents property, plant, and equipment, net by geographic region (in thousands):
June 30, 2026December 31, 2025
United States$94,288 $79,499 
Europe163,238 147,303 
Rest of World15,809 15,801 
$273,335 $242,603